No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes

被引:10
作者
Ahrén, B
Gutniak, M
机构
[1] Univ Lund, Dept Med, Malmo, Sweden
[2] Karolinska Inst, Vallingby Med Ctr, Stockholm, Sweden
关键词
D O I
10.1530/eje.0.1370643
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To examine whether glucagon-like peptide I (GLP-1), which has been suggested as a new therapeutic agent in type 2 diabetes, affects circulating islet amyloid polypeptide (IAPP), a B-cell peptide of potential importance for diabetes pathophysiology. Design: GLP-1 was administered in a buccal tablet (400 mu g) to seven healthy subjects and nine subjects with type 2 diabetes. Serum IAPP and insulin levels were measured before and after GLP-1 administration. Results: In the fasting state, serum IAPP was 4.1 +/- 0.3 pmol/l in the controls vs 9.8 +/- 0.9 pmol/l in the subjects with type 2 diabetes (P < 0.001). IAPP correlated with insulin only in controls (r=0.74, P=0.002) but not in type 2 diabetes (r=0.26, NS). At 15 min after GLP-1, circulating IAPP increased to 6.0+/-0,5 pmol/l in controls (P=0.009) and to 13.8+/-1.2 pmol/l in type 2 diabetes (P=0.021). In both groups, serum insulin increased and blood glucose decreased compared with placebo. In controls serum IAPP increased in parallel with insulin (r=0.79, P=0.032), whereas in type 2 diabetes the increase in IAPP did not correlate with the increase in insulin. Conclusion: Type 2 diabetes is associated with elevated circulating IAPP; GLP-1 stimulates IAPP secretion both in healthy human subjects and in type 2 diabetes; IAPP secretion correlates with insulin secretion only in healthy subjects and not in type 2 diabetes.
引用
收藏
页码:643 / 649
页数:7
相关论文
共 44 条
[1]  
AHREN B, 1990, INT J PANCREATOLOGY, V9, P1
[2]   FAILURE TO ESTABLISH ISLET AMYLOID POLYPEPTIDE (AMYLIN) AS A CIRCULATING BETA-CELL INHIBITING HORMONE IN MAN [J].
BRETHERTONWATT, D ;
GILBEY, SG ;
GHATEI, MA ;
BEACHAM, J ;
BLOOM, SR .
DIABETOLOGIA, 1990, 33 (02) :115-117
[3]   EFFECTS OF MEAL INGESTION ON PLASMA AMYLIN CONCENTRATION IN NIDDM AND NONDIABETIC HUMANS [J].
BUTLER, PC ;
CHOU, J ;
CARTER, WB ;
WANG, YN ;
BU, BH ;
CHANG, D ;
CHANG, JK ;
RIZZA, RA .
DIABETES, 1990, 39 (06) :752-756
[4]   ISLET AMYLOID - AN ENIGMA OF TYPE-2 DIABETES [J].
CLARK, A .
DIABETES-METABOLISM REVIEWS, 1992, 8 (02) :117-132
[5]   PLASMA ISLET AMYLOID POLYPEPTIDE LEVELS IN OBESITY, IMPAIRED GLUCOSE-TOLERANCE AND NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
ENOKI, S ;
MITSUKAWA, T ;
TAKEMURA, J ;
NAKAZATO, M ;
ABURAYA, J ;
TOSHIMORI, H ;
MATSUKARA, S .
DIABETES RESEARCH AND CLINICAL PRACTICE, 1992, 15 (01) :97-102
[6]   ISLET AMYLOID POLYPEPTIDE PLASMA-CONCENTRATIONS IN INDIVIDUALS AT INCREASED RISK OF DEVELOPING TYPE-2 (NON-INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
ERIKSSON, J ;
NAKAZATO, M ;
MIYAZATO, M ;
SHIOMI, K ;
MATSUKURA, S ;
GROOP, L .
DIABETOLOGIA, 1992, 35 (03) :291-293
[7]   AT THE CUTTING EDGE - GLUCAGON-LIKE PEPTIDE-1(7-37)/(7-36)AMIDE IS A NEW INCRETIN [J].
FEHMANN, HC ;
GOKE, R ;
GOKE, B .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1992, 85 (1-2) :C39-C44
[8]   CELL AND MOLECULAR-BIOLOGY OF THE INCRETIN HORMONES GLUCAGON-LIKE PEPTIDE-I AND GLUCOSE-DEPENDENT INSULIN RELEASING POLYPEPTIDE [J].
FEHMANN, HC ;
GOKE, R ;
GOKE, B .
ENDOCRINE REVIEWS, 1995, 16 (03) :390-410
[9]   ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS [J].
GUTNIAK, M ;
ORSKOV, C ;
HOLST, JJ ;
AHREN, B ;
EFENDIC, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) :1316-1322
[10]   Potential therapeutic level of glucagon-like peptide I achieved in humans by a buccal tablet [J].
Gutniak, MK ;
Larsson, H ;
Heiber, SJ ;
Juneskans, OT ;
Holst, JJ ;
Ahren, B .
DIABETES CARE, 1996, 19 (08) :843-848